People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Pharmaceuticals, Biotechnology, Computers, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $140.2M | $703.0M | 2012 |
| Aduro Biotech, Inc. | — | Biotechnology | Series C | $131.0M | $2.1B | 2013 |
| Pinteon Therapeutics, Inc. | — | Biotechnology | Series B | $39.2M | $603.8M | 2014 |
| Vigeo Therapeutics, Inc. | — | Biotechnology | Series A | $17.6M | $195.3M | 2015 |
| Meissa Vaccines Inc | — | Biotechnology | Series A | $15.2M | $503.1M | 2019 |
| BiddingForGood, Inc. | — | Computers | Seed | $4.6M | $91.1M | 2011 |
| Natural Polymer International Corp | — | Manufacturing | Seed | $2.6M | $31.6M | 2012 |
Stephanie O'Brien at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephanie O'Brien on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 2 | 13 |
| Jason Dinges | 2 | 8 |
| Peter B. Finn | 1 | 11 |
| Isaac Cheng | 1 | 9 |
| Frank McCormick | 1 | 7 |
| Steven Kelly | 1 | 4 |
| Ross Haghighat | 1 | 4 |
| Cedric Francois | 1 | 4 |
| Harris Fishman | 1 | 4 |
| Jonathan Carson | 1 | 3 |
| Alec Machiels | 1 | 3 |
| Sinclair Dunlop | 1 | 3 |
| Stephen Green | 1 | 3 |
| Douglas Onsi | 1 | 3 |
| Jeffrey L. Ives | 1 | 3 |
| Andrew Kang | 1 | 3 |
| Pascal Deschatelets | 1 | 2 |
| Gregory W. Schafer | 1 | 2 |
| Stephen T. Isaacs | 1 | 2 |
| David Darst | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.